President Donald J. Trump has announced steps by the administration to lower drug prices for Medicare beneficiaries, including reaching agreements with manufacturers to lower the prices of certain drugs[3][5]. CMS reported that the second round of price negotiations yielded 15 drugs with negotiated maximum fair prices (MFPs) that are estimated to result in a net savings of 44%, or approximately $12 billion, over projected Medicare spending for these drugs[4][5]. These MFP prices will be effective January 1, 2027, and, along with the first 10 negotiated drugs, will increase the number of drugs with negotiated prices to 25[5]. Among the covered drugs are products used to treat cancer, diabetes, asthma, and other chronic conditions, and CMS identifies these drugs as high spending items in the Part D program[5]. The White House has also announced a series of agreements with a wide range of pharmaceutical companies, and examples cite significant price reductions for some upcoming direct patient purchasing programs through adminstrative initiatives[3]. The Administration asserts that these actions build on the law's enforcement and previous implementations of price negotiation in Medicare and are intended to improve affordability and reduce costs for Medicare patients[4][3].